Celyad S.A. Actions au porteur o.N.
Sector and Industry
Healthcare, Healthcare Equipment
Performance (1Y)
38.66%
Market Cap
9.44 Mil.
P/E Ratio
8.76
Dividend Yield
0.00 %
Earnings per Share
0.02 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Abbott Laboratories | 185.26 Bil. | 39.29 Bil. | 33.69 | -53.32 % | 0.00 | - |
| Intuitive Surgical Inc | 171.24 Bil. | 8.92 Bil. | 71.93 | +17.90 % | 0.00 | - |
| Boston Scientific Corp | 120.40 Bil. | 17.79 Bil. | 49.17 | +49.88 % | 0.00 | - |
| Stryker Corp. | 114.47 Bil. | 22.26 Bil. | 41.85 | +3.99 % | 0.00 | - |
| Medtronic PLC | 90.93 Bil. | 31.27 Bil. | 22.35 | -4.61 % | 0.00 | - |
| Siemens Healthineers AG | 51.40 Bil. | 23.38 Bil. | 24.04 | +10.40 % | 0.00 | - |
| Hoya Corp | 48.59 Bil. | 5.43 Bil. | 35.69 | +17.33 % | 0.00 | - |
| Becton Dickinson and Co. | 45.46 Bil. | 19.79 Bil. | 32.18 | -3.33 % | 0.00 | - |
| Edwards Lifesciences Corp | 42.15 Bil. | 5.38 Bil. | 47.11 | -27.44 % | 0.00 | - |
| Alcon AG | 33.20 Bil. | 9.24 Bil. | 38.41 | -7.56 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 0.26 G | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 10:33:30 AM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 0.26 | 0.212 |
| PREV. DAY'S PRICE | 0.211 | (07/20) |
| CHANGE DAY BEFORE | +0.05 | 23.22 % |
| 52 WEEK HIGH / LOW | 0.594 (02/17) | 0.1115 (01/28) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026 | 2027 | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -0.33 | -0.14 | 0.02 | - | - |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | - | - |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | - | 8.76 | - | - |
PRICE - BOOK RATIO | - | - | 2.89 | - | - |
PRICE - SALES RATIO | 98.35 | 158.59 | 374.55 | - | - |
PRICE - CASH FLOW RATIO | - | - | - | - | - |
Master Data
| WKN | A1W7Q9 |
| ISIN | BE0974260896 |
| SYMBOL | 1C0 |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | CELYAD S.A. |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | Euro |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Healthcare Equipment |
| NUMBER OF SHARES | 44.76 Mil. |
| MARKET CAPITALISATION | 9.44 Mil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 2.43 % | -4.09 % | -25.70 % | 53.45 % | -38.66 % | -59.73 % | -93.97 % | 33.97 % |
| HIGH | 0.26 | 0.28 | 0.34 | 0.59 | 0.59 | 1.07 | 4.48 | 0.59 |
| LOW | 0.15 | 0.15 | 0.15 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 |
Dividende
pro Aktie
CELYAD S.A. does not deliver dividend information
Company profile
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.